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Incorporation of Salivary Gland Ultrasonography Into the 
American College of Rheumatology/European League 
Against Rheumatism Criteria for Primary Sjögren’s 
Syndrome
Jolien F. van Nimwegen,  Esther Mossel, Konstantina Delli,  Martha S. van Ginkel, Alja J. Stel,  
Frans G. M. Kroese, Fred K. L. Spijkervet, Arjan Vissink , Suzanne Arends, and Hendrika Bootsma
Objective. To assess whether the addition of salivary gland ultrasonography (SGUS) or replacement of current cri-
teria items by SGUS influences the performance of the American College of Rheumatology (ACR)/European League 
Against Rheumatism (EULAR) criteria for primary Sjögren’s syndrome.
Methods. Included were consecutive patients with complete data on all ACR/EULAR items (n = 243) who under-
went SGUS in our primary Sjögren’s syndrome expertise center. Clinical diagnosis by the treating physician was used 
as the gold standard. Separate analyses were performed for patients who underwent labial or parotid gland biopsies. 
The average score for hypoechogenic areas in 1 parotid and 1 submandibular gland was determined (range 0–3). 
Next, performance of the ACR/EULAR criteria was evaluated after addition of SGUS or replacement of current items 
by SGUS.
Results. Receiver operating characteristic analysis showed an optimal cutoff value of ≥1.5 for SGUS. The optimal 
weight for SGUS positivity was 1. Cutoff for ACR/EULAR fulfilment remained ≥4. In patients who underwent a labial 
gland biopsy (n = 124), the original criteria showed an area under the curve (AUC) of 0.965, sensitivity of 95.9%, and 
specificity of 92.2%. After the addition of SGUS, the AUC was 0.966, with a sensitivity of 97.3% and specificity of 
90.2%. In patients who underwent a parotid gland biopsy (n = 198), similar results were found. Sensitivity of the cri-
teria decreased substantially when SGUS replaced salivary gland biopsy or anti- SSA antibodies, while performance 
remained equal when SGUS replaced the ocular staining score, Schirmer’s test, or unstimulated whole saliva flow.
Conclusion. Validity of the ACR/EULAR criteria remains high after incorporation of SGUS. With SGUS, clinicians 
are offered a larger array of tests to evaluate fulfillment of the ACR/EULAR criteria.
INTRODUCTION
Primary Sjögren’s syndrome (SS) is a common systemic 
autoimmune disease affecting the exocrine glands, manifesting as 
keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth) 
(1,2). Patients also often experience fatigue and several extraglan-
dular manifestations (2).
Several classification criteria sets for primary SS have been 
developed during recent years. Of these, the 2002 American 
European Consensus Group (AECG) criteria have most often 
been used in daily clinical practice for many years (3–5). Corner-
stones of this criteria set are a focus score ≥1 in a salivary gland 
biopsy and the presence of anti- SSA/anti- SSB antibodies (3). 
These criteria take both subjective sicca symptoms and objective 
measures for the ocular and oral symptoms into account so that 
equal weights are assigned to the oral and ocular components 
(3). However, the AECG criteria have not been endorsed by the 
American College of Rheumatology (ACR) and  European League 
Against  Rheumatism (EULAR) (4,5). In an effort to reach inter-
national consensus regarding classification criteria for  primary 
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SS, recently the 2016 ACR/EULAR criteria were  developed, 
 consisting of items from the 2002 AECG and the 2012 ACR cri-
teria (3–6). Both EULAR and the ACR have endorsed the ACR/
EULAR criteria, and the criteria have been validated in multiple 
external cohorts (7–9). The ACR/EULAR criteria show high sen-
sitivity and specificity regardless of the type of biopsy (parotid or 
labial) taken to assess the salivary gland focus score (8).
Upon a closer look at the ACR/EULAR criteria, a few key 
points become evident. First, salivary gland histopathology and 
the presence of anti- SSA antibodies deservedly remain corner-
stones in the classification of primary SS. Second, tear gland 
involvement is measured using a functional test (Schirmer’s test) 
and by imaging of structural damage of the ocular surface  (ocular 
staining score [OSS]), while salivary gland involvement is only 
evaluated using a functional test (unstimulated whole saliva flow 
[UWS]). Removal of sialography and scintigraphy from the crite-
ria is an advantage of the ACR/EULAR criteria, considering the 
invasiveness and limited validity of these procedures (4,10–12). 
However, the ACR/EULAR criteria now lack a test that measures 
structural salivary gland damage.
Currently, B- mode salivary gland ultrasonography (SGUS) is 
increasingly applied to assess structural changes of the salivary 
glands in primary SS. SGUS is noninvasive, nonirradiating, inex-
pensive, relatively easy to perform in an outpatient setting, and 
can be repeated for follow- up. Previous studies have demon-
strated that SGUS has good accuracy to differentiate primary 
SS from nonprimary SS (9,13–17). Many scoring systems are 
applied for SGUS, but recent analyses have shown that limit-
ing scoring to hypoechogenic areas in both the submandibular 
and parotid gland on 1 side suffices for accurate differentia-
tion between primary SS and non primary SS (18). Scoring of 
hypoechogenic areas showed good intra- and interobserver 
reliability (19,20). This reduction of the scoring system further 
increases the feasibility of the technique for common applica-
tion in a diagnostic setting.
In clinical cohort studies, the addition of SGUS to the 
AECG and ACR criteria has been shown to increase the sen-
sitivity of these criteria, with a minor decrease in their spec-
ificity (10,21). Unfortunately, SGUS was not tested as a new 
diagnostic technique in the cohorts in which the ACR/EULAR 
criteria were  developed and validated and not considered to 
be included in the criteria. Therefore, our primary objective 
was to assess whether the presence of hypoechogenic areas 
on SGUS as a criteria item influences the performance of the 
ACR/EULAR criteria. The second objective was to evaluate 
the performance of the ACR/EULAR criteria when replacing 
current items with SGUS. Both objectives were evaluated in 
a large cohort of patients  clinically suspected of primary SS.
PATIENTS AND METHODS
Study population. The study population for this cohort 
study consisted of all eligible consecutive patients who underwent 
an SGUS examination in the University Medical Center Groningen 
between October 2014 and July 2017. SGUS was performed as 
a routine diagnostic imaging technique in new patients clinically 
suspected of primary SS as well as during baseline visits of pri-
mary SS patients included in the Efficacy and Safety of Abata-
cept in Patients With Primary Sjögren’s Syndrome phase III trial 
(NCT02067910) or the Registry of Sjögren’s Syndrome in the 
University Medical Center Groningen: Longitudinal observational 
cohort study.
Exclusion criteria were age <18 years, the presence of 
an associated systemic autoimmune disease (e.g., rheuma-
toid arthritis, systemic lupus erythematosus), or current use of 
biologic disease- modifying antirheumatic drugs. Patients lack-
ing a clinical diagnosis and patients with an incomplete diag-
nostic evaluation according to the ACR/EULAR criteria were 
also excluded. The clinical diagnosis by experienced treating 
physicians was used as the gold standard in all analyses. If 
a diagnosis was not clearcut, consensus was achieved by 
consulting at least 1 other experienced physician. This study 
was conducted in accordance with the Declaration of Helsinki. 
The research protocol was approved by the Medical Ethics 
Committee of the University Medical Center Groningen (METc 
2018/309), which waived the requirement of written informed 
consent.
SGUS. SGUS was performed using the MyLabSeven scan-
ner (Esaote), equipped with a high- resolution linear probe (4–13 
MHz). All SGUS images were scored by JFvN, KD, or AJS, who 
previously showed good interobserver agreement when scoring 
hypoechogenic areas (19). Median intraclass correlation coeffi-
cients were 0.74 for parotid glands and 0.71 for submandibular 
glands. The presence of hypoechogenic areas was scored as: 0 = 
no hypoechogenic areas, 1 = a few scattered areas, 2 = several 
areas, and 3 = numerous hypoechogenic areas (17). The aver-
age score for the presence of hypoechogenic areas (range 0–3) in 
the submandibular and parotid gland on the right side was deter-
SIGNIFICANCE & INNOVATIONS
• Salivary gland ultrasonography (SGUS) can be 
added to the American College of Rheumatology 
(ACR)/ European League Against Rheumatism (EULAR) 
 criteria or replace the ocular staining score, Schirmer’s 
test, or unstimulated whole saliva flow.
• The optimal weight of SGUS in the ACR/EULAR cri-
teria is 1. The optimal cutoff of the modified ACR/
EULAR score remains ≥4.
• The validity of the ACR/EULAR criteria remains high 
after incorporation of SGUS.
• The modified criteria enable a stepwise approach 
for classification, starting with anti-SSA antibodies 
and SGUS.
INCORPORATION OF SGUS INTO THE ACR/EULAR CRITERIA FOR PRIMARY SS |      585
mined, which was previously shown to accurately differentiate 
between primary SS and non primary SS (18). If the right parotid 
or submandibular gland could not be scored (e.g., because of 
previous removal of that gland), scores of the left side were used. 
Receiver operating characteristic analysis was used to determine 
the optimal cutoff value for SGUS to identify patients who were 
clinically diagnosed with primary SS by the treating physicians by 
choosing the cutoff for which the sum of sensitivity and specificity 
was the highest.
Classification according to the original ACR/EULAR 
criteria. All included patients had been subjected to a complete 
multidisciplinary evaluation according to the ACR/EULAR criteria 
(4,5), including a labial gland biopsy, a parotid gland biopsy, or 
both. Separate analyses were performed, in which classification 
according to the ACR/EULAR criteria was determined using the 
outcomes of either labial or parotid gland biopsy results. Patients 
who underwent both a labial and parotid gland biopsy were 
included in both analyses, with the results of either their labial or 
parotid gland biopsy being used to determine the ACR/EULAR 
classification.
Incorporation of SGUS into the ACR/EULAR criteria. 
SGUS positivity was added as an item to the ACR/EULAR cri-
teria. To keep the original criteria applicable, the weight of the 
original criteria items was kept as they were, i.e., 3 points for 
the presence of anti- SSA antibodies and a focus score ≥1; and 
1 point for an abnormal UWS, Schirmer’s test, and OSS score 
(4,5). To select the optimal weight of SGUS, separate analyses 
of the performance of the modified ACR/EULAR criteria were 
 performed, assigning a weight of either 1, 2, or 3 points for a 
positive SGUS.
Replacement of current ACR/EULAR criteria items 
by ultrasound. Next, 5 additional criteria sets were developed, 
in which SGUS replaced 1 of the current items. The weight of the 
original items was again kept equal to the original criteria, and 
the optimal weight of the SGUS item was determined by doing 
separate analyses using a weight of 1, 2, or 3 points for a positive 
SGUS.
Statistical analysis. Statistical analyses were executed 
using SPSS software, version 23. Receiver operating charac-
teristic analysis was performed to determine the accuracy of 
the original ACR/EULAR score, the ACR/EULAR score with the 
addition of SGUS, and the ACR/EULAR score with SGUS as 
replacement of original items to predict the clinical diagnosis. 
The area under the curve (AUC) was interpreted as no discrim-
ination (0 to 0.5), or with the accuracy judged as poor (>0.5 
to 0.7), fair (>0.7 to 0.8), good (>0.8 to 0.9), or excellent (>0.9 
to 1.0) (22). Optimal cutoff values of the different ACR/EULAR 
scores were determined by choosing the cutoff for which the 
sum of sensitivity and specificity was the highest. Patients were 
then classified according to this cutoff for the original and mod-
ified criteria sets. Finally, absolute agreement, sensitivity, and 
specificity of the original and modified ACR/EULAR criteria sets, 
with clinical diagnosis as the gold standard, were determined 
and compared.
RESULTS
SGUS was performed in 363 patients. Of these, 243 patients 
were eligible for inclusion (Figure 1). Of the 243 included patients, 
45  underwent only a labial biopsy, 119 underwent only a parotid 
gland biopsy, and 79 underwent both a labial and parotid gland 
Figure 1. Flow chart of patient inclusion. * = missing items were salivary gland biopsy (n = 72), Schirmer’s test (n = 4), ocular staining score 
(n = 2), and unstimulated whole saliva flow (n = 2). In the majority of these patients, either the patients could be classified as primary Sjögren’s 
syndrome (pSS) without the need of a positive salivary gland biopsy result, or a positive biopsy result would not have resulted in a clinical 
diagnosis of primary SS. SGUS = salivary gland ultrasound; bDMARDs = biologic disease- modifying antirheumatic drugs; ACR = American 
College of Rheumatology; EULAR = European League Against Rheumatism.
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biopsy. Including the patients who underwent both biopsies, 124 
underwent a labial biopsy, and 198 underwent a parotid gland 
biopsy.
Characteristics of patients with primary SS and non primary 
SS are shown in Table 1. All included patients fulfilled the entry cri-
teria of the ACR/EULAR criteria. The characteristics of the patients 
who underwent a labial gland biopsy were similar to those of the 
patients who underwent a parotid gland biopsy (data not shown). 
The median time between SGUS and salivary biopsies was 7 
months for labial gland biopsies and 6 months for parotid gland 
biopsies.
Performance of SGUS. The accuracy of SGUS to predict 
clinical diagnosis was good, with an AUC of 0.860 (95% confi-
dence interval [95% CI] 0.821–0.900), and an optimal cutoff value 
of ≥1.5. SGUS was therefore considered positive when the aver-
age score for the presence of hypoechogenic areas in 1 parotid 
and 1 submandibular gland was ≥1.5. Based on this cutoff point, 
SGUS was positive in 106 patients with primary SS and 6 patients 
with non primary SS and negative in 41 patients with primary SS 
and 90 patients with non primary SS. Absolute agreement with 
clinical diagnosis was 80.7%, sensitivity was 72.1%, and speci-
ficity was 93.8%.
Performance of ACR-EULAR criteria with addition 
of SGUS. Supplementary Table 1,  parts A and B, available on 
the Arthritis Care & Research web site at http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24017/ abstract, shows the perfor-
mance of the ACR/EULAR criteria when SGUS was added to 
the criteria, using a weight of 1, 2, or 3 for a positive SGUS. 
The performance of the ACR/EULAR criteria including SGUS 
was highest when a positive SGUS was assigned a weight of 1 
point. The optimal cutoff point of the original ACR/EULAR score 
to discriminate between primary SS and non primary SS was 
confirmed to be ≥4. After the addition of SGUS to the ACR/
EULAR criteria with a weight of 1 point, the optimal cutoff point 
of the modified ACR/EULAR score to discriminate between pri-
mary SS and non primary SS remained ≥4 (see Supplementary 
Table 1, parts A and B, available at http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24017/ abstract). Based on these results, 
in the following analyses a cutoff of ≥4 was used for the original 
and modified ACR/EULAR score. A positive SGUS results in an 
increase of 1 point in the modified ACR/EULAR score (Table 2, 
parts A and B).
In patients who underwent a labial gland biopsy (n = 124), 
the original ACR/EULAR criteria showed an AUC of 0.965 (95% 
CI 0.932–0.997) to predict clinical diagnosis (Figure 2). Absolute 
agreement with clinical diagnosis was 94.4%, sensitivity was 
95.9%, and specificity was 92.2%. After the addition of SGUS, 
the modified ACR/EULAR criteria showed an AUC of 0.966 (95% 
CI 0.934–0.998), absolute agreement remained the same, sensi-
tivity slightly increased to 97.3%, and specificity slightly decreased 
to 88.2%.
The same analyses were performed in patients who under-
went a parotid gland biopsy (n = 198), and similar results were 
found (Figure 2). In this group, the original criteria showed an 
AUC of 0.954 (95% CI 0.925–0.984) to predict clinical diagno-
sis. Absolute agreement with clinical diagnosis was 92.9%, sen-
sitivity was 91.4%, and specificity was 95.1%. After the addition 
of SGUS, the modified ACR/EULAR criteria showed an AUC 
of 0.964 (95% CI 0.939–0.989), absolute agreement remained 
the same, sensitivity slightly increased to 92.3%, and specific-
ity slightly decreased to 93.8%. To summarize, the addition of 
SGUS to the ACR/EULAR criteria resulted in negligible changes 
in the performance of the criteria and did not change its optimal 
cutoff point.






Age, mean ± SD years 53 ± 14 52 ± 14
Female sex 131 (89) 81 (84)
SGUS score, median (IQR) 2.0 (1.0–2.5) 0.5 (0.5–1.0)
SGUS score ≥1.5 106 (72) 10 (10)
FS ≥1 in labial gland biopsy† 64 (88) 5 (10)
FS ≥1 in parotid gland 
biopsy‡
89 (76) 2 (2)
Anti- SSA positive 125 (85) 9 (9)
Ocular staining score ≥5 70 (48) 11 (12)
Schirmer ≤5 mm/5 minute 113 (77) 56 (58)
Unstimulated whole saliva 
≤0.1 ml/minute
105 (71) 42 (44)
* Values are the number (%) unless indicated otherwise. SS = 
Sjögren’s syndrome; SGUS = salivary gland ultrasonography; IQR = 
interquartile range; FS = focus score (foci/4 mm2). 
† N = 124 (73 primary SS, 51 nonprimary SS). 
‡ N = 198 (117 primary SS, 81 non primary SS). 





Original ACR/EULAR criteria 
Focal lymphocytic sialadenitis and FS ≥1 3
Anti- SSA positive 3
OSS ≥5 in at least 1 eye 1
Schirmer’s test ≤5 mm/5 minutes in at least 1 eye 1
UWS flow rate ≤0.1 ml/minute 1
Modified ACR/EULAR criteria: addition of ultrasound 
Focal lymphocytic sialadenitis and FS ≥1 3
Anti- SSA positive 3
OSS ≥5 in at least 1 eye 1
Schirmer’s test ≤5 mm/5 minute in at least 1 eye 1
UWS flow rate ≤0.1ml/minute 1
Average SGUS score for hypoechogenic areas ≥1.5 1
* For both sets, patients with a score of ≥4 are classified as primary 
Sjögren’s syndrome. ACR = American College of Rheumatology; 
EULAR = European League Against Rheumatism; FS = focus score 
(foci/4 mm2); OSS = ocular staining score; UWS = unstimulated whole 
saliva flow; SGUS = salivary gland ultrasonography. 
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Performance of ACR-EULAR criteria with replacement 
of items by SGUS. For the following analysis, 5 modified sets of 
criteria were used, in which one of the original items was replaced 
with SGUS. When SGUS replaced current criteria items in patients 
who underwent a labial gland biopsy (n = 124), the optimal weight 
for SGUS was again 1 point, regardless of which original criteria 
item was replaced by SGUS (see Supplementary Table 2, available 
on the Arthritis Care & Research web site at http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24017/ abstract). The optimal cutoff point to 
discriminate between primary SS and non primary SS remained ≥4.
When SGUS replaced the labial gland biopsy or anti- SSA 
antibodies, there was a considerable decrease in accuracy and 
sensitivity, while there was only a slight decrease in specificity 
compared to the original criteria (Table 3A and Figure 3A). On the 
other hand, when SGUS replaced the OSS, Schirmer’s test, or 
UWS, no major changes in accuracy, sensitivity, and specificity 
occurred.
The same analyses were performed in patients who under-
went a parotid gland biopsy (n = 198). When SGUS replaced 
the OSS, Schirmer’s test, or UWS, the optimal weight for SGUS 
was again 1 point (see Supplementary Table 3, available on the 
Arthritis Care & Research web site at http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24017/ abstract), with only minor changes 
in sensitivity and specificity and even an increase in accuracy 
(Table  3B and Figure  3B). When SGUS replaced the parotid 
gland biopsy or anti- SSA antibodies, the optimal weight for 
SGUS was 3 points. However, regardless of whether SGUS was 
assigned 1, 2, or 3 points in these analyses, accuracy of the 
ACR/EULAR criteria dropped substantially (see Supplementary 
Table 3, available at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24017/ abstract).
To summarize, SGUS can replace the OSS, Schirmer’s test, 
or UWS in the classification of primary SS without major changes 
in the performance of the criteria. The salivary gland biopsy or the 
measurement of anti- SSA antibodies, on the other hand, cannot 
be completely replaced by SGUS since this replacement led to a 
considerable decrease in the performance of the criteria.
DISCUSSION
In this large clinical cohort study, we aimed to investigate the 
performance of the ACR/EULAR criteria when a positive SGUS 
was added to the criteria. The performance of the ACR/EULAR 
criteria was best when SGUS was assigned a weight of 1 point.
Figure 2. Receiver operating characteristic curves of the original 
American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) criteria and adjusted criteria with the addition 
of salivary gland ultrasonography (SGUS). AUC = area under the 
curve; 95% CI = 95% confidence interval.
T3
Table 3. Performance of the original and modified ACR/EULAR criteria sets with salivary gland ultrasonography (SGUS) replacing current items*
AUC 95% CI Agreement Sensitivity Specificity
Patients with labial gland biopsy (n = 124)
Original ACR/EULAR criteria 0.965 0.932–0.997 94.4 95.9 92.2
SGUS replacing labial gland biopsy 0.903 0.849–0.957 87.9 82.2 94.1
SGUS replacing anti- SSA antibodies 0.943 0.902–0.985 89.5 86.3 94.1
SGUS replacing OSS 0.964 0.931–0.996 93.5 95.9 88.2
SGUS replacing Schirmer’s test 0.969 0.938–1.000 93.5 94.5 92.2
SGUS replacing UWS 0.967 0.937–0.998 93.5 97.3 88.2
Patients with parotid gland biopsy (n = 198)
Original ACR/EULAR criteria 0.954 0.925–0.984 92.9 91.4 95.1
SGUS replacing parotid gland biopsy 0.925 0.887–0.962 88.4 83.8 95.1
SGUS replacing anti- SSA antibodies 0.918 0.879–0.956 86.9 79.5 97.5
SGUS replacing OSS 0.964 0.938–0.990 93.4 92.3 95.1
SGUS replacing Schirmer’s test 0.964 0.939–0.989 89.9 84.6 97.5
SGUS replacing UWS 0.969 0.946–0.992 92.9 90.6 96.3
* Values are the percentage unless indicated otherwise. In all criteria sets, a weight of 1 point for SGUS and cutoff value of ≥4 for fulfilment of 
the criteria was used. ACR = American College of Rheumatology; EULAR = European League Against Rheumatism; AUC = area under the curve; 
95% CI = 95% confidence interval; OSS = ocular staining score; UWS = unstimulated whole saliva flow. 
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In the first part of this study, we showed that addition of 
SGUS to the ACR/EULAR criteria only marginally increased sen-
sitivity and marginally decreased specificity, while overall accu-
racy remained the same. Although the addition of SGUS did not 
improve the accuracy of the ACR/EULAR criteria in our cohort, it 
improves their feasibility in clinical practice, by allowing rheumatol-
ogists to choose from a larger array of tests.
Previously, 2 other studies incorporated SGUS in the ACR/
EULAR classification criteria (23,24). In the study by Le Goff et al 
(23), in which the AECG and ACR/EULAR classification crite-
ria were compared, the addition of SGUS to the ACR/EULAR 
criteria was also investigated. However, the authors arbitrarily 
assigned a weight of 1 point to a positive SGUS and used the 
same cutoff value as the original ACR/EULAR criteria (i.e., ≥4). 
Figure  3. Receiver operating characteristic curves of the original American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) criteria and adjusted criteria with replacement of original items by salivary gland ultrasonography (SGUS). A, ACR/EULAR 
criteria including labial gland biopsy outcome. B, ACR/EULAR criteria including parotid gland biopsy outcome. AUC = area under the curve; 
95% CI = 95% confidence interval.
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In our study, we confirmed statistically that the optimal weight to 
assign to SGUS was indeed 1 point and that the optimal cutoff 
value to classify a patient as having primary SS remained ≥4. In 
the study by Le Goff et al (23), similar results were found regard-
ing the performance of the ACR/EULAR criteria after addition 
of SGUS, i.e., sensitivity was slightly increased and specificity 
slightly decreased.
In the study by Takagi et al (24), the weight of the original 
criteria items was also kept. In contrast to our study, 3 points 
were assigned to SGUS positivity, and the optimal cutoff point 
to discriminate between SS and non- SS increased to ≥5. The 
combined ACR/EULAR and SGUS scoring system showed an 
improved accuracy compared to the original criteria. Unfortu-
nately, a fair comparison between the study of Takagi et al (24) 
and ours cannot be made since the methodology of their study 
differed greatly from ours. Importantly, complete data regarding 
the ACR/EULAR items were only available in a small subset of 
the included patients (62 of 213 patients); Saxon’s test, which 
measures stimulated whole saliva, was used instead of UWS, and 
patients with secondary SS were not excluded. Furthermore, a 
different, more complicated SGUS score was used.
In the second part of this study, the performance of the ACR/
EULAR criteria was evaluated when SGUS replaced current clas-
sification items. We found that SGUS could replace the OSS, 
Schirmer’s test, or UWS in the classification of primary SS without 
decreasing the accuracy of the ACR/EULAR criteria. However, 
when SGUS replaced the salivary gland biopsy in the classifica-
tion of primary SS or the measurement of anti- SSA antibodies, the 
performance of the criteria significantly decreased.
In a previous study, we showed that the combination of a pos-
itive SGUS and the presence of anti- SSA antibodies had a positive 
predictive value of 97% for classification as primary SS, according 
to the ACR/EULAR criteria (14). Based on these results, Mossel 
et al suggested that for classification purposes, the first step of a 
classification evaluation could be SGUS and determination of anti- 
SSA positivity. When both are positive, patients can already be 
classified as primary SS. The current study confirms these results 
because the combination of anti- SSA positivity and SGUS posi-
tivity is indeed enough for fulfillment of the adjusted ACR/EULAR 
criteria. As the next step in the evaluation for classification, we rec-
ommend a salivary gland biopsy since the sensitivity of the ACR/
EULAR criteria decreased substantially when the salivary gland 
biopsy was completely replaced by SGUS. When it comes to clin-
ically diagnosing a patient with primary SS, on the other hand, we 
prefer a full evaluation, including SGUS and as many items of the 
ACR/EULAR criteria as possible, to allow a  clinician to decide on 
the best possible treatment for that particular patient.
When SGUS is added to the ACR/EULAR criteria, the cut-
off of 4 points can be fulfilled solely based on Schirmer’s test, 
OSS, UWS, and SGUS. In our database, this combination only 
occurred in 1 patient, who was clinically diagnosed as non- SS. 
Therefore, we cannot draw a definite conclusion about the validity 
of the ACR/EULAR criteria in this specific subgroup. Based on 
our expert opinion, we would recommend only classifying such a 
patient as primary SS if a positive biopsy result or anti- SSA anti-
bodies are also present until there are more data available regard-
ing this subgroup.
In this study, we used a simplified SGUS scoring system, 
similar to the ones used by other groups (15,21,23). However, the 
lack of a consensus scoring system complicates the incorpora-
tion of SGUS into the ACR/EULAR criteria. Jousse- Joulin et al (20) 
recently published an atlas with consensual definitions of SGUS 
abnormalities. The next step will be to agree on a consensus scor-
ing system with a validated cutoff. As soon as a validated cutoff 
is set, SGUS hopefully will be incorporated into the ACR/EULAR 
criteria. The addition of SGUS, as a measure for structural dam-
age of the salivary glands, would balance the ACR/EULAR crite-
ria by including 2 items to measure tear as well as salivary gland 
 involvement.
A strong point of our study is the use of a large cohort of 
patients from daily clinical practice, including patients with pri-
mary SS as well as non primary SS sicca, with complete data for 
all ACR/EULAR items. Furthermore, analyses were performed 
separately for patients who underwent a labial and/or a parotid 
gland biopsy, which makes our data relevant to all diagnostic 
centers regardless of the type of biopsy performed. A potential 
limitation of the study is the use of clinical diagnosis performed 
by expert clinicians working in a tertiary referral center for primary 
SS, instead of expert consensus, as the gold standard. However, 
using expert consensus as the gold standard would also have 
introduced bias depending on the familiarity of the experts with 
SGUS in primary SS.
In conclusion, the validity of the ACR/EULAR criteria remains 
high after incorporation of SGUS. SGUS is noninvasive, nonirra-
diating, inexpensive, and relatively easy to perform in an outpa-
tient setting and could replace OSS, Schirmer’s test, or UWS in 
centers with less access to these tests. Incorporation of SGUS 
into the ACR/EULAR criteria improves their feasibility in clinical 
practice by allowing rheumatologists to choose from a larger array 
of tests. The modified criteria enable a step- wise approach for 
classification, starting with determination of anti- SSA antibodies 
and SGUS, which decreases the number of invasive salivary gland 
biopsies needed for classification.
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